论文部分内容阅读
据新华社报道,瑞士医药监管部门日前在国内全面叫停羊胎素抗衰老疗法。瑞士医药监管机构强调,截至目前从未批准任何使用活细胞疗法(羊胎素疗法)的产品许可或其他相关许可,相反这些监管部门警告:“活细胞疗法的有效性未经科学证实,健康风险却早已显现,这一疗法可能导致过敏、注射处脓肿、血液感染甚至是动物病原体传染。”监管部门明确指出:“所有从事生产、进口、配销或使用非法羊胎素产品的医院及从业人员必须停止此类活动或立即申请相关执照或批准,对部分违法医院及个人,瑞士药物监管局已提起刑事诉讼。”
According to Xinhua News Agency reported that the Swiss pharmaceutical regulatory authorities in the country recently stopped a comprehensive anti-aging Placenta therapy. Swiss pharmaceutical regulator stressed that so far no product license or other related permission to use live cell therapy (placenta therapy) has been approved, on the contrary these regulators warn: “The effectiveness of living cell therapies have not been scientifically proven, healthy Risks have long been apparent and may lead to allergies, abscesses at the injection site, bloodstream infections and even infections with animal pathogens. ”Regulatory authorities make it clear that:“ All hospitals engaged in the manufacture, import, distribution or use of illegal placenta products And practitioners must stop such activities or apply for relevant licenses or approvals immediately, criminal proceedings have been filed against some illegal hospitals and individuals and the Swiss Drug Administration. ”